Significant capital flows continue shaping biotech innovation landscape. Kriya Therapeutics raises $313 million to advance gene therapies in ophthalmic, metabolic, and neurologic diseases. Calidi Biotherapeutics closes $6.9 million public offering to support targeted genetic medicines development. Neurovalens secures £6 million for growth of non-invasive neurostimulation devices. Ot the med-tech front, QuidelOrtho completes $3.4 billion debt refinancing aimed at reducing amortization and extending maturities, providing financial flexibility for growth initiatives.